Navigation Links
Roche's Investigational Polymerase Inhibitor, Combined with PEGASYS(R) and COPEGUS(TM), Shows Potent Antiviral Activity in Treatment of Chronic Hepatitis C at Four Weeks
Date:11/2/2007

atment. PEGASYS is also contraindicated in hepatic decompensation with Child-Pugh score greater than or equal to 6 in cirrhotic CHC patients coinfected with HIV before or during treatment. PEGASYS is also contraindicated in neonates and infants because it contains benzyl alcohol. Benzyl alcohol is associated with an increased incidence of neurological and other complications in neonates and infants, which are sometimes fatal. PEGASYS and COPEGUS therapy is additionally contraindicated in patients with a hypersensitivity to COPEGUS or any of its components, in women who are pregnant, men whose female partners are pregnant, and patients with hemoglobinopathies (eg, thalassemia major, sickle-cell anemia).

COPEGUS THERAPY SHOULD NOT BE STARTED UNLESS A REPORT OF A NEGATIVE PREGNANCY TEST HAS BEEN OBTAINED IMMEDIATELY PRIOR TO INITIATION OF THERAPY. Women of childbearing potential and men must use two forms of effective contraception during treatment and during the 6 months after treatment has concluded. Routine monthly pregnancy tests must be performed during this time. If pregnancy should occur during treatment or during 6 months post-therapy, the patient must be advised of the significant teratogenic risk of COPEGUS therapy to the fetus. Healthcare providers and patients are strongly encouraged to immediately report any pregnancy in a patient or partner of a patient during treatment or during 6 months after treatment cessation to the Ribavirin Pregnancy Registry at 1-800-593-2214.

Chronic hepatitis C (CHC) patients with cirrhosis may be at risk of hepatic decompensation and death when treated with alpha interferons, including PEGASYS. During treatment, patients' clinical status and hepatic function should be closely monitored, and PEGASYS treatment should be immediately discontinued if decompensation (Child-Pugh score greater than or equal to 6) is observed.

The most common adverse events reported for PEGASYS and COPEGUS combination therapy observed
'/>"/>

SOURCE Roche
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Phase 3 Results for Dabigatran Etexilate, an Investigational Oral Anticoagulant, Presented Today at the XXIst Congress of the International Society on Thrombosis and Haemostasis
2. An Investigational Study Released at ADA Showed that Initial Combination Therapy with Januvia (sitagliptin) and Metformin Led to Improvement in Markers of Beta Cell Function in Patients with Type 2 Diabetes
3. Late Breaking Data Released at ADA Showed that the Investigational Use of Januvia and Metformin as Initial Combination Therapy Provided Significant Glucose Lowering Efficacy over 54 Weeks in Patients with Type 2 Diabetes
4. Investigational Study Demonstrated a Re-Establishment of Clinical Improvement with Orencia (Abatacept) in Children with Juvenile Idiopathic Arthritis upon Re-Introduction of Therapy
5. Mercks Investigational Migraine Treatment MK-0974 Significantly Improved Migraine Pain on Several Efficacy Measures in a Phase II Study
6. Data Demonstrated Metastatic Melanoma Response to Investigational Immunotherapy Ipilimumab
7. Investigational Drug Cediranib (AZD2171) Shows Promise in Patients With Recurrent Glioblastoma (GBM)
8. Additional New Data from Satraplatin SPARC Phase 3 Investigational Trial Presented at ASCO Annual Meeting
9. Additional New Data from Satraplatin SPARC Phase 3 Investigational Trial Presented at ASCO Annual Meeting
10. Investigational Cancer Drug Pertuzumab Shows Promising Results in Advanced Breast Cancer When Combined with Herceptin
11. Shire Announces Positive Results of Studies With Guanfacine Extended Release, An Investigational Nonstimulant Medication Filed for the Treatment of ADHD in Children and Adolescents
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/19/2014)... 19, 2014 Today, iHealth Lab Inc. announced it ... Ltd. for its first institutional round of funding. The ... global reach, accelerate growth and innovation, and invest in ... investment, Xiaomi Ventures will join iHealth,s board of directors, ... and ecommerce. "We are very pleased to ...
(Date:9/19/2014)... 19, 2014  The board of directors of AbbVie ... cash dividend of $0.42 per share.  ... stockholders of record at the close of business on ... a global, research-based biopharmaceutical company formed in 2013 following ... its expertise, dedicated people and unique approach to innovation ...
(Date:9/19/2014)... 2014 Research and Markets has announced ... Autoimmune, Cancer, Diarrhea, Mental Disorder) Market - Forecast to 2023" ... of this report, the human microbiome market is segmented by ... market is expected to be valued as $294 million in ... 22.3% within the forecast period of 2019-2023. The market is ...
Breaking Medicine Technology:iHealth Raises $25 Million to Fuel Growth and Global Market Share 2Global Human Microbiome (Diabetes, Obesity, Autoimmune, Cancer, Diarrhea, Mental Disorder) Market - Forecast to 2023 2Global Human Microbiome (Diabetes, Obesity, Autoimmune, Cancer, Diarrhea, Mental Disorder) Market - Forecast to 2023 3
... Va., Sept. 20, 2011 Rock Creek Pharmaceuticals, a ... ), announced that on September 19, 2011 a utility ... Office ("PTO"). This utility patent application is based on ... various products containing anatabine and the administration of anatabine ...
... Sept. 20, 2011 /PRNewswire-Asia/ -- Chindex International, Inc. (NASDAQ: ... providing health care services in China through the operations ... care hospitals and affiliated ambulatory clinics, today announced that ... to be held October 13-14, 2011 at Nomura,s Singapore ...
Cached Medicine Technology:Rock Creek Pharmaceuticals Discloses Further Anatabine Patent Filing 2Rock Creek Pharmaceuticals Discloses Further Anatabine Patent Filing 3Rock Creek Pharmaceuticals Discloses Further Anatabine Patent Filing 4
(Date:9/19/2014)... In partnership with Raw Beauty NYC, OC healthcare ... project’s social media efforts. StudioPMG is honored to be a ... of beauty as it applies to disabled women. , ... Baer and Vanessa Silberman, who wanted to create a photo ... Dixon, Wendy Crawford, Susan Solman and Sabrina Cohen later joined ...
(Date:9/19/2014)... September 19, 2014 -- Recent two-generation approaches to ... are receiving increasing attention from researchers, advocates, and ... to enable them to move to jobs that ... early care and education for children, these programs ... However, according to a new report from ...
(Date:9/19/2014)... 2014 As summer vacations end and everyone ... NY now reminds area patients about the reality and impact ... population affected by gum disease, there is simply not an ... 20 years Dr. Krishnan has treated patients with varying degrees ... patients that come in due to common symptoms such as ...
(Date:9/19/2014)... Recently, Top10BestSEOHosting.com has compared many professional ... Web Hosting and Bluehost are the best VPS ... to most people, VPS (Virtual Private Server) is ... into many servers, each of which has the ... dedicated computer,” the manager of Top10BestSEOHosting.com says. ...
(Date:9/19/2014)... and large protein complexes are notoriously difficult to study ... very difficult, if not impossible, to crystallize, but also ... The result is that when a structure can be ... reveals a mosaic-like spread of protein domains that sometimes ... Brunger. (2014), Acta Cryst . D70, 2241-2255; ...
Breaking Medicine News(10 mins):Health News:OC Healthcare Agency StudioPMG Partners with The Raw Beauty Project ™ NYC 2014 2Health News:A two generation lens: Current state policies fail to support families with young children 2Health News:New York Periodontist Dr. Prabha Krishnan Now Raises Awareness about the Dangers of Untreated Decay, Gingivitis and Gum Disease During Self-Awareness Month 2Health News:New York Periodontist Dr. Prabha Krishnan Now Raises Awareness about the Dangers of Untreated Decay, Gingivitis and Gum Disease During Self-Awareness Month 3Health News:Top10BestSEOHosting.com: JustHost is One of the Best VPS Suppliers in 2014 2Health News:A refined approach to proteins at low resolution 2Health News:A refined approach to proteins at low resolution 3
... LA JOLLA, Calif., Jan. 29 There,s a rumble ... their feet and planting,their behinds on yoga mats and ... World Health Research shows that,74% of Americans have expressed ... A surge in popularity of Pilates, Yoga, Qigong, Meditation, ...
... recurrence and painful side effects, small trial finds , , ... to treating deep vein thrombosis, injecting the clot-busting drug ... the risk of complications and recurrence, a small U.S. ... of blood thinners appears to completely destroy the clots, ...
... Opportunities for the Company, -- Potentially Denotes a Positive Sign ... ... Process, NEW YORK and HAIKOU, China, ... Board: CPHI),which develops, manufactures, and markets generic and brand,bio-pharmaceutical products in ...
... Ind., Jan. 29 , ... Quarter Highlights, -- Net Sales of $1.07 billion represents an increase of 15% ... 15% reported (10% constant currency), -- Diluted EPS were ... period, and $1.18 adjusted, an increase of 16% over the prior year ...
... MS -- Cold and flu season is upon ... year, according to,the Centers for Disease Control. A cold ... in children and the elderly. Early detection,is key, especially ... days,of the infection,s onset., (Photo: http://www.newscom.com/cgi-bin/prnh/20080129/NYTUFNS1 ...
... for blood clots in the legs appears to be safe ... February issue of Radiology. The study found that injecting or ... deep vein thrombosis (DVT) and reduces the risk of subsequent ... clear blood clots rapidly and safely, restoring blood flow in ...
Cached Medicine News:Health News:Are People Asking Their Doctors?: Halo Rejuvenator a Holistic Remedy for Headache, Neck and Shoulder Pain 2Health News:Are People Asking Their Doctors?: Halo Rejuvenator a Holistic Remedy for Headache, Neck and Shoulder Pain 3Health News:Clot-Busting Drug Offers New Approach to DVT 2Health News:Clot-Busting Drug Offers New Approach to DVT 3Health News:China Pharma Holdings, Inc. Receives Chinese SFDA Approval for Generic Bumetanide Injection 2Health News:China Pharma Holdings, Inc. Receives Chinese SFDA Approval for Generic Bumetanide Injection 3Health News:Zimmer Reports Fourth Quarter and 2007 Financial Results 2Health News:Zimmer Reports Fourth Quarter and 2007 Financial Results 3Health News:Zimmer Reports Fourth Quarter and 2007 Financial Results 4Health News:Zimmer Reports Fourth Quarter and 2007 Financial Results 5Health News:Zimmer Reports Fourth Quarter and 2007 Financial Results 6Health News:Zimmer Reports Fourth Quarter and 2007 Financial Results 7Health News:Zimmer Reports Fourth Quarter and 2007 Financial Results 8Health News:Zimmer Reports Fourth Quarter and 2007 Financial Results 9Health News:Zimmer Reports Fourth Quarter and 2007 Financial Results 10Health News:Zimmer Reports Fourth Quarter and 2007 Financial Results 11Health News:Zimmer Reports Fourth Quarter and 2007 Financial Results 12Health News:Zimmer Reports Fourth Quarter and 2007 Financial Results 13Health News:Zimmer Reports Fourth Quarter and 2007 Financial Results 14Health News:Zimmer Reports Fourth Quarter and 2007 Financial Results 15Health News:Zimmer Reports Fourth Quarter and 2007 Financial Results 16Health News:Zimmer Reports Fourth Quarter and 2007 Financial Results 17Health News:Flu and Fever Detection Facts for Dr. Mom 2Health News:Flu and Fever Detection Facts for Dr. Mom 3Health News:New therapy effectively treats deep vein thrombosis 2
Provides the security of braided polyester suture and ease of an automated knot for vascular closure of 5-8Fr....
The ACE Alera clinical chemistry system serves a wide variety of chemistry diagnostic needs with the power of a large floor model analyzer in an easily integrated and economizing compact footprint of...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
Medicine Products: